- NYSE: ABT is on course to leap by around 10% on Thursday.
- Abbott Laboratories has received an FDA approval for its BinaxNOW COVID-19 Card test.
- The rapid, cheap, and instrument-free probe is touted as a game-changer.
A game-changer in fighting coronavirus – and this time it is not a vaccine or a cure, but a rapid test coming from a well-established company. Abbott Laboratories (NYSE: ABT) may now begin selling its Aboott BinaxNow COVID-19 Ag Card Test. The Food and Drug Administration (FDA) has given its emergency authorization, allowing mass production of the test.
Abbott expects to manufacture around ten million units in September, 50 million in October, and continue ramping up output later on. The Chicago-based firm – which is in businesses since the 19th century – said that results of the test are out after 15 minutes – far faster than the standard PCR ones.
Abbott Laboratories also said that the tests have a demonstrated sensitivity of 97.1% and specificity of 98.5% in a clinical study. The tests are also cheap – only $5, and do not necessitate any labs or instruments.
Using such rapid tests could help capture asymptomatic COVID-19 carriers and isolate them before they infect others. Moreover, it could allow a quick resumption of normal life. Air passengers can undergo these quick tests, assuring with a high degree of certainty that no coronavirus-carrying patient is on board.
Overall, the product is promising.
ABT Stock Dividend
NYSE: ABT is changing hands at over $112 in pre-market trading on Thursday, an increase of nearly 10%. It is critical to note that Abbott Laboratories is a large pharmaceutical firm worth over $180 billion, and such a move is substantial.
Moreover, sales of BinaxNOW could boost income and the bottom line, leading to a higher dividend. The mere prospects of topping its 2019 revenue of $31.9 billion could also trigger an increase in Abbott's payout to shareholders.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD consolidates near 19-month peak as traders await US PCE Price Index
AUD/USD oscillates in a range below the 0.6900 mark, as traders opt to move to the sidelines ahead of the US PCE Price Index. In the meantime, the RBA's hawkish stance, the optimism led by additional monetary stimulus from China, the prevalent risk-on mood, and a bearish USD continue to act as a tailwind for the pair.
USD/JPY holds above 145.00 after the Tokyo CPI inflation data
The USD/JPY pair attracts some buyers to near 145.20 on Friday during the early Asian session. The pair gains ground near three-week highs after the Tokyo Consumer Price Index. The attention will shift to the US Personal Consumption Expenditures Price Index for August, which is due later on Friday.
Gold price holds steady near record peak; looks to US PCE data from fresh impetus
Gold price consolidates below the all-time high set on Thursday amid overbought conditions on the daily chart and the risk-on mood, though dovish Fed expectations continue to act as a tailwind. Bulls, meanwhile, prefer to wait for the release of the US PCE Price Index before placing fresh bets.
Ethereum could retest $2,707 resistance following increasing ETF inflows and uptrend in funding rates
Ethereum traded around $2,640 on Thursday, up more than 2% following increased bullish bias among investors, as evidenced by ETH ETF net inflows and an uptrend in funding rates. However, investors may be wary of a potential correction from ETH's rising exchange reserve.
RBA widely expected to keep key interest rate unchanged amid persisting price pressures
The Reserve Bank of Australia is likely to continue bucking the trend adopted by major central banks of the dovish policy pivot, opting to maintain the policy for the seventh consecutive meeting on Tuesday.
Five best Forex brokers in 2024
VERIFIED Choosing the best Forex broker in 2024 requires careful consideration of certain essential factors. With the wide array of options available, it is crucial to find a broker that aligns with your trading style, experience level, and financial goals.